First Time Loading...

ESSA Pharma Inc
NASDAQ:EPIX

Watchlist Manager
ESSA Pharma Inc Logo
ESSA Pharma Inc
NASDAQ:EPIX
Watchlist
Price: 3.31 USD +16.55% Market Closed
Updated: Sep 27, 2023

Net Margin
ESSA Pharma Inc

0%
Current
0%
Average
-6.4%
Industry
Negative for the last year
0%
Negative average
0%
Worse than average
Worse than industry value

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
0%
=
Net Income
-27.4m
/
Revenue
0

Net Margin Across Competitors

Net Margin Comparison
ESSA Pharma Inc Competitors

Country Company Market Cap Net
Margin
CA
ESSA Pharma Inc
NASDAQ:EPIX
146m USD N/A
US
Abbvie Inc
NYSE:ABBV
268B USD
15%
US
Amgen Inc
NASDAQ:AMGN
143B USD
30%
US
Gilead Sciences Inc
NASDAQ:GILD
93.7B USD
20%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
90.8B USD
36%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
89.6B USD
35%
AU
CSL Ltd
ASX:CSL
123B AUD
16%
US
Seagen Inc
NASDAQ:SGEN
39.8B USD
-34%
US
Moderna Inc
NASDAQ:MRNA
37.4B USD
43%
US
Biogen Inc
NASDAQ:BIIB
37B USD
27%
NL
argenx SE
NASDAQ:ARGX
26.7B USD
-173%
ESSA Pharma Inc
NASDAQ:EPIX
Country CA
Market Cap 146m USD
Net Margin N/A
Abbvie Inc
NYSE:ABBV
Country US
Market Cap 268B USD
Net Margin
15%
Amgen Inc
NASDAQ:AMGN
Country US
Market Cap 143B USD
Net Margin
30%
Gilead Sciences Inc
NASDAQ:GILD
Country US
Market Cap 93.7B USD
Net Margin
20%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Country US
Market Cap 90.8B USD
Net Margin
36%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Country US
Market Cap 89.6B USD
Net Margin
35%
CSL Ltd
ASX:CSL
Country AU
Market Cap 123B AUD
Net Margin
16%
Seagen Inc
NASDAQ:SGEN
Country US
Market Cap 39.8B USD
Net Margin
-34%
Moderna Inc
NASDAQ:MRNA
Country US
Market Cap 37.4B USD
Net Margin
43%
Biogen Inc
NASDAQ:BIIB
Country US
Market Cap 37B USD
Net Margin
27%
argenx SE
NASDAQ:ARGX
Country NL
Market Cap 26.7B USD
Net Margin
-173%

Net Margin Distribution

Net Margin Distribution
Biotechnology Industry

Profitability Report

View the profitability report to see the full profitability analysis for ESSA Pharma Inc.

Full Profitability Report

See Also

Summary
EPIX intrinsic value, competitors valuation, and company profile.
DCF Valuation
EPIX stock valuation using Discount Cash Flow valuation method.
Relative Valuation
EPIX stock valuation using valuation multiples.
Wall Street Estimates
EPIX price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
EPIX stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Other Stocks
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
0%
=
Net Income
-27.4m
/
Revenue
0
What is the Net Margin of ESSA Pharma Inc?

Based on ESSA Pharma Inc's most recent financial statements, the company has Net Margin of 0%.

ALPHA SPREAD
Join more than 75,700+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Pricing Terms of Service Privacy Policy Affiliate Program

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2023 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.